Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986288 · 1 trial · 1 indication
Safety releated events for Cohorts 1A, 1B and 2B.
A DLT is an adverse event or abnormal lab value not related to disease progression, illness, or other medications. The DLT evaluation period is 5 weeks (35 days) for both BMS-986288 monotherapy and combination dose escalation. Toxicities beyond this period will inform final dose decisions. Participants who discontinue due to a DLT or complete the 5-week period after receiving at least 2 doses are considered DLT-evaluable. Those who withdraw early or receive fewer than 2 doses for non-DLT reasons are not evaluable and may be replaced. Participants with dose delays for non-DLT reasons remain evaluable if they receive at least 2 doses within 8 weeks.
The percentage of all treated participants whose BOR is either CR or PR by BICR per RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| Arm A: BMS-986288 Monotherapy | EXPERIMENTAL | - |
| Arm B: BMS-986288 in combination with Nivolumab | EXPERIMENTAL | - |
| Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986288 | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Regorafenib | DRUG | Specified dose on specified days |
Inclusion Criteria: * Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy * Eastern Cooperative Oncology Group Performance Status of 0 or 1 * Received, and t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-986288 is an investigational small molecule being studied for the treatment of advanced cancer. It is being evaluated in patients with advanced solid cancers, including in combination with another immunotherapy drug. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BMS-986288 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced cancer.
BMS-986288 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The Phase 1 trial has been completed, and the drug is being studied for the treatment of advanced cancer.
BMS-986288 has been studied in a Phase 1 clinical trial with the identifier NCT03994601. This trial evaluated BMS-986288 alone and in combination with nivolumab in patients with advanced solid cancers. The trial was completed and enrolled 219 participants across multiple countries.
No, BMS-986288 is not the same as nivolumab. BMS-986288 is an investigational small molecule being studied for advanced cancer, while nivolumab is a separate immunotherapy drug. In the clinical trial NCT03994601, BMS-986288 was studied both alone and in combination with nivolumab.